256-270 of 305
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®Recent updates from adjuvant trials in HR+/HER2- EBC
Nadia Harbeck, MD, PhD
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Interprofessional Coordination of Adverse Event Management
MinuteCE®Interprofessional Coordination of Adverse Event Management
Nadia Harbeck, MD, PhD
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®Maximizing Adherence and Persistence via Patient Engagement
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Nadia Harbeck, MD, PhD
- advertisement
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CEWarm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Caroline Piatek, MD
Irina Murakhovskaya, MD
Shubham Pant, MD, MBBS
Ritu Salani, MD, MBA
Significance of HER2 Expression in Solid Tumors
MinuteCE®Significance of HER2 Expression in Solid Tumors
Shubham Pant, MD, MBBS
Ritu Salani, MD, MBA
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Shubham Pant, MD, MBBS
- advertisement
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®Diversity in HER2 Expression Among Gynecologic Cancers
Ritu Salani, MD, MBA
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Shubham Pant, MD, MBBS
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Ritu Salani, MD, MBA
